Evaluation of Graft Material in Coronary Artery Bypass Grafting (CABG)
Mid-term Patency of Radial Artery and No Touch Saphenous Vein as Grafts in CABG; A Randomised Controlled Trial.
1 other identifier
interventional
108
1 country
1
Brief Summary
The aim of the study is to evaluate the patency in different kinds of vessels used as graft material in coronary artery bypass grafting. The hypothesis is that vein grafts harvested with a pedicle of surrounding tissue have the same, or better, patency compared to radial grafts and that skeletonisation of the left internal mammary artery does not effect the patency for this graft.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for not_applicable
Started Jan 2004
Longer than P75 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 1, 2004
CompletedPrimary Completion
Last participant's last visit for primary outcome
November 1, 2010
CompletedStudy Completion
Last participant's last visit for all outcomes
November 1, 2010
CompletedFirst Submitted
Initial submission to the registry
March 7, 2011
CompletedFirst Posted
Study publicly available on registry
March 8, 2011
CompletedMarch 8, 2011
September 1, 2010
6.8 years
March 7, 2011
March 7, 2011
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Functional grafts defined as opened or closed.
Up to 5 years after surgery.
Secondary Outcomes (1)
Degree of stenosis in implanted grafts.
Up to 5 years after surgery.
Interventions
Bypass of stenoses in coronary arteries using different types os vessels as conduit.
Eligibility Criteria
You may qualify if:
- Isolated coronary artery disease embracing all three main branches of the coronary artery tree.
You may not qualify if:
- Kidney insufficiency (Creatinine \> 120 µmol/L)
- War-farin anticoagulation therapy
- Ejection fraction \< 40%
- Repeat operation
- Other concurrent sur-gery
- Signs of reduced circulation in non-dominant hand
- Other severe illness, or if the patient declines to participate.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Region Örebro Countylead
- Swedish Heart Lung Foundationcollaborator
- Regional Clinical Researchcollaborator
Study Sites (1)
Dept of Cardiothoracic Surgery, Orebro University Hospital
Örebro, 701 85, Sweden
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- STUDY CHAIR
Lars Norgren, MD, PhD, Prof.
OREBRO UNIVERSITY
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- SINGLE
- Who Masked
- OUTCOMES ASSESSOR
- Purpose
- TREATMENT
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
Study Record Dates
First Submitted
March 7, 2011
First Posted
March 8, 2011
Study Start
January 1, 2004
Primary Completion
November 1, 2010
Study Completion
November 1, 2010
Last Updated
March 8, 2011
Record last verified: 2010-09